癌症进展
癌癥進展
암증진전
ONCOLOGY PROGRESS
2014年
1期
89-92
,共4页
贾春祎%张立新%张晓凯%邹勤光%王启文
賈春祎%張立新%張曉凱%鄒勤光%王啟文
가춘의%장립신%장효개%추근광%왕계문
非小细胞肺癌%脑转移%福莫司汀%尼莫司汀
非小細胞肺癌%腦轉移%福莫司汀%尼莫司汀
비소세포폐암%뇌전이%복막사정%니막사정
non-small cell lung cancer%brain metastases%fotemustine%nimustine
目的:观察对比福莫司汀及尼莫斯汀治疗非小细胞肺癌脑转移的疗效及不良反应。方法将60例患者随机分入福莫司汀组和尼莫司汀组。福莫司汀组给予福莫司汀100 mg/m2, iv, d1、 d8、 d15,停药4~5周后福莫司汀100 mg/m2, iv, d1、 d21,休息3周后重复1次;尼莫司汀组给予尼莫司汀2~3mg/kg, iv, d1,停药4~6周后重复给药1次。观察两组的治疗有效率及不良反应情况。结果福莫斯司汀组和尼莫司汀组的有效率分别为83.3%和60.0%,两组间差异有统计学意义( P<0.05)。福莫司汀组发生3~4级胃肠道反应的患者占16.7%,略高于尼莫司汀组(10%),但差异无统计学意义。重度骨髓抑制情况福莫司汀组比尼莫司汀组轻。结论福莫司汀治疗晚期非小细胞肺癌脑转移具有临床推广价值。
目的:觀察對比福莫司汀及尼莫斯汀治療非小細胞肺癌腦轉移的療效及不良反應。方法將60例患者隨機分入福莫司汀組和尼莫司汀組。福莫司汀組給予福莫司汀100 mg/m2, iv, d1、 d8、 d15,停藥4~5週後福莫司汀100 mg/m2, iv, d1、 d21,休息3週後重複1次;尼莫司汀組給予尼莫司汀2~3mg/kg, iv, d1,停藥4~6週後重複給藥1次。觀察兩組的治療有效率及不良反應情況。結果福莫斯司汀組和尼莫司汀組的有效率分彆為83.3%和60.0%,兩組間差異有統計學意義( P<0.05)。福莫司汀組髮生3~4級胃腸道反應的患者佔16.7%,略高于尼莫司汀組(10%),但差異無統計學意義。重度骨髓抑製情況福莫司汀組比尼莫司汀組輕。結論福莫司汀治療晚期非小細胞肺癌腦轉移具有臨床推廣價值。
목적:관찰대비복막사정급니막사정치료비소세포폐암뇌전이적료효급불량반응。방법장60례환자수궤분입복막사정조화니막사정조。복막사정조급여복막사정100 mg/m2, iv, d1、 d8、 d15,정약4~5주후복막사정100 mg/m2, iv, d1、 d21,휴식3주후중복1차;니막사정조급여니막사정2~3mg/kg, iv, d1,정약4~6주후중복급약1차。관찰량조적치료유효솔급불량반응정황。결과복막사사정조화니막사정조적유효솔분별위83.3%화60.0%,량조간차이유통계학의의( P<0.05)。복막사정조발생3~4급위장도반응적환자점16.7%,략고우니막사정조(10%),단차이무통계학의의。중도골수억제정황복막사정조비니막사정조경。결론복막사정치료만기비소세포폐암뇌전이구유림상추엄개치。
Objective To observe the efficacy and adverse reactions of fotemustine compared with nimustine in non-small cell lung cancer ( NSCLC) patients with brain metastasis. Method 60 patients were randomized into fotemustine or nimustine group. Administration method in fotemustine group was 100 mg/m2 , iv, d1, d8, d15, then an interruption of 4-5 weeks, followed by a maintenance period of fotemustine 100mg/m2 , iv, d1, d21, which was repeated after three weeks of rest, and evaluation of efficacy and safety was carried out then. Nimustine group accepted nimustine 2-3 mg/kg, iv, d1, then the same regimen resumed after an interruption of 4-6 weeks. Result Response rates ( RR) in fotemustine and nimus-tine group were 83.3%vs 60.0%, and there was statistical difference between them ( P<0.05) . Some 16.7%patients in fo-emustine group developed gastrointestinal disorders of grade 3-4, which were slightly higher than that of the nimusitine group (10%), while the difference was not obvious, and the seriousness of myelosuppression in fotemustine group was compara-tively lighter. Conclusion Fotemustine is worth promoting for non-small cell lung cancer with brain metastasis in clinic.